Helen Louise Collins, CHIEF MEDICAL OFFICER at Enliven Therapeutics, Inc. (ELVN), sold 80,000 shares at $35.10 ($2.8M) on 2026-03-25, disclosed to the SEC on 2026-03-27.
Scheduled sale ($2.8M) by CHIEF MEDICAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $35.10 | 40,000 | $1.4M | 50.0% |
| 2 | $35.10 | 40,000 | $1.4M | 50.0% |
| Total | $35.10 avg | 80,000 | $2.8M | 100% |
| Filing → |
| ELVN | SELL | 2026-07-21 | $263K | — | Filing → |
| ELVN | SELL | 2026-06-22 | $219K | — | Filing → |
| ELVN | SELL | 2026-05-20 | $199K | — | Filing → |